Liquid Biopsy Biomarkers in Urine: A Route towards Molecular Diagnosis and Personalized Medicine of Bladder Cancer.
Liquid Biopsy Biomarkers in Urine: A Route towards Molecular Diagnosis and Personalized Medicine of Bladder Cancer.
复制标题
尿液中的液体活检生物标志物：膀胱癌分子诊断和个性化医疗的途径。
DOI：
10.3390/jpm11030237
复制
发表时间：
2021-03-23
影响因子：
--
通讯作者：
Terracciano D
中科院分区：
文献类型：
--
作者：
Ferro M;La Civita E;Liotti A;Cennamo M;Tortora F;Buonerba C;Crocetto F;Lucarelli G;Busetto GM;Del Giudice F;de Cobelli O;Carrieri G;Porreca A;Cimmino A;Terracciano D
膀胱癌（BC）具有发病率高、复发率高、基因组不稳定、突变程度高等特点。目前，膀胱镜检查结合细胞学常规用于诊断、预后和疾病监测。这种方法通常与几种副作用、患者的不适和高经济负担相关。因此，对于BC患者的临床管理，存在对非侵入性、敏感、快速和廉价的生物标志物的基本需求。在这种情况下，液体活检是一种非常有前途的工具，在过去十年中得到了广泛的研究。液体活检可能是患者选择精准医疗的基础，无论是在治疗选择还是治疗效果的实时监测方面。已经提出了几种不同的尿液生物标志物用于BC中的液体活检，包括DNA甲基化和突变、基于蛋白质的测定、非编码RNA和mRNA签名。在这篇综述中，我们总结了最先进的不同可用的测试有关其潜在的临床应用BC检测，预后，监测和治疗反应。
Bladder cancer (BC) is characterized by high incidence and recurrence rates together with genomic instability and elevated mutation degree. Currently, cystoscopy combined with cytology is routinely used for diagnosis, prognosis and disease surveillance. Such an approach is often associated with several side effects, discomfort for the patient and high economic burden. Thus, there is an essential demand of non-invasive, sensitive, fast and inexpensive biomarkers for clinical management of BC patients. In this context, liquid biopsy represents a very promising tool that has been widely investigated over the last decade. Liquid biopsy will likely be at the basis of patient selection for precision medicine, both in terms of treatment choice and real-time monitoring of therapeutic effects. Several different urinary biomarkers have been proposed for liquid biopsy in BC, including DNA methylation and mutations, protein-based assays, non-coding RNAs and mRNA signatures. In this review, we summarized the state of the art on different available tests concerning their potential clinical applications for BC detection, prognosis, surveillance and response to therapy.
登录
查看更多内容
DOI：
10.1158/1055-9965.epi-08-0192
发表时间：
2008-10
期刊：
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
影响因子：
--
作者：
Brait M;Begum S;Carvalho AL;Dasgupta S;Vettore AL;Czerniak B;Caballero OL;Westra WH;Sidransky D;Hoque MO
通讯作者：
Hoque MO
DOI：
10.3322/caac.21244
发表时间：
2014-09
期刊：
CA: a cancer journal for clinicians
影响因子：
--
作者：
Berindan-Neagoe I;Monroig Pdel C;Pasculli B;Calin GA
通讯作者：
Calin GA
DOI：
10.1158/1055-9965.epi-11-0067
发表时间：
2011-07
期刊：
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
影响因子：
--
作者：
Chung W;Bondaruk J;Jelinek J;Lotan Y;Liang S;Czerniak B;Issa JP
通讯作者：
Issa JP
影响因子：
6.6
作者：
Carpinito, GA;Stadler, WM;Hayden, CL
通讯作者：
Hayden, CL
DOI：
10.1196/annals.1368.045
发表时间：
2006-01-01
期刊：
CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM IV
影响因子：
--
作者：
Bryzgunova, Olga E.;Skvortsova, Tatyana E.;Laktionov, Pavel P.
通讯作者：
Laktionov, Pavel P.